Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

BACKGROUND: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. METHODS: IMPACT was a 52-week, randomized, double-blind, multicenter Phase III s...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Respir Res
Prif Awduron: Day, Nicola C., Kumar, Subramanya, Criner, Gerard, Dransfield, Mark, Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kaisermann, Morrys C., Kilbride, Sally, Lange, Peter, Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert, Lipson, David A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2020
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275457/
https://ncbi.nlm.nih.gov/pubmed/32503599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01398-w
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg